GERN - Considering The Merits Of A Gamble On Geron Corporation
2024-04-11 15:56:04 ET
Summary
- The FDA advisory committee voted 12-2 in favor of imetelstat's clinical profile in lower-risk myelodysplastic syndromes.
- The PDUFA target date for GERN's imetelstat NDA is June 16, 2024.
- An interim analysis in GERN's IMpactMF study in myelofibrosis isn't expected until H1'25.
...
Considering The Merits Of A Gamble On Geron Corporation